re already under clinical development as anti-cancer drugs. The authors write, "Further investigation of the antiviral efficacy of [enzyme] inhibitors maybe warranted. The wealth of existing knowledge regarding the design and in vivo pharmacology of these inhibitors may facilitate development of an anti-Ebola-virus therapy."

The work was done in collaboration with Nancy J. Sullivan, Ph.D., of NIAID's Vaccine Research Center.

The paper's lead author, Kartik Chandran, Ph.D., of Brigham and Women's Hospital and Harvard Medical School, is supported by a career development award from the NIAID Regional Centers of Excellence for Biodefense and Emerging Infectious Diseases Research (RCE) program. In 2003, NIAID funded the establishment of eight RCEs nationwide. The RCE program supports interdisciplinary research aimed at new and improved therapies, vaccines, diagnostics and other tools to protect against the threat of bioterrorism and other emerging and re-emerging diseases.

'"/>

Contact: Anne A. Oplinger
aoplinger@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
14-Apr-2005

Page: 1 2
Related medicine news :

1. Scientists train nano-building blocks to take on new shapes, as reported in Science
2. Scientists find war vets hand dexterity determines susceptibility to PTSD
3. Scientists develop method to track immune system enzyme in live animals
4. Scientists from the CIMA investigate a molecule for diagnosing hypertensive cardiopathy
5. Scientists equip bacteria with custom chemo-navigational system
6. Scientists find missing link to understand how plants make vitamin C
7. Scientists and polar explorers brave the elements in support of CryoSat-2
8. Scientists identify cells responsible for relapse after treatment in common childhood cancer
9. Scientists progress in successful tissue engineering
10. Scientists re-grow dental enamel from cultured cells
11. Scientists create dual-modality microbeads to improve identification of disease biomarkers